ncRNA basic information
ncRNA ID:
MI0000442
ncRNA Database:
miRBase
ncRNA Name:
miR-122
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
ABCB1,ABCF2
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00997 (APRD00185, DB05331, DB05847)
Drug Name:
Doxorubicin
Drug Method:
The present study investigated whether restoration of miR-122 in HCC cells could alter the cell cycle distribution and the expression of multidrug resistance (MDR)-related genes (ABCB1, ABCC1, ABCG2 and ABCF2). After overexpression of miR-122 in HepG2 cells treated or untreated with doxorubicin doses, total RNAs and protein extracts were isolated for application of QRT-PCR and western blotting techniques. Moreover, cell cycle distribution was monitored by flow cytometry. Our results revealed that, the over expression of miR-122 in HepG2 cells treated or untreated with doxorubicin could modulate the sensitivity of cells to chemotherapeutic drug through downregulation of MDR-related genes, ABCB1 and ABCF2. Interpretation of cell cycle distribution revealed that, the anti-proliferative effect of miR-122 is associated with the accumulation of cells in G0/G1 phase. Moreover, treatment with miR-122 and doxorubicin resulted in high percentage of HCC cells in G0/G1 phase. Taken together, our findings revealed that, overexpression of miR-122 inhibited HCC cell growth by inducing cell cycle arrest and this arrest is associated with down-regulation of MDR-related genes.
Drug Response:
sensitive
Cancer basic information
Cancer:
hepatocellular carcinoma
Tissue/Cell:
cell line (HepG2)
Other information
Title:
Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.
Journal:
Indian J Clin Biochem
Published:
2018
PubMed ID:
29371766